These are ARK Genomic Revolution ETF's own holdings, not the firm's. Percentages are of the stock positions in its latest filing — the fund's cash and bonds are not included. This actively managed fund seeks out the companies building the tools of genomics: sequencing platforms, gene-editing systems and CRISPR medicines that are turning DNA into routine work in the clinic and the hospital. It is not a broad slice of the biotech sector. It concentrates on the builders of a handful of overlapping platforms — precision medicine, gene therapy and synthetic biology, and the diagnostic software that runs on them — and is willing to ride the sharp swings its positions take while those platforms work out. Where ARK's other themes reach toward robotics, autonomous transport, energy and blockchain, this one stays closer to the tissue and the test tube. It shares the firm's signature research-heavy, open style — daily published research, transparent trades and portfolios built top-down from multi-year forecasts rather than trailing earnings — but its risk is concentrated in a single technological wave instead of spread across many. The fund launched on October 31, 2014, as one of ARK Invest's original active exchange-traded products, conceived under Cathie Wood, the firm's founder. She still oversees the strategy as ARK's chief investment officer and the portfolio manager named on the fund today, supported by a dedicated team of genomics analysts.
$1.23B
Period in review
ARK Genomic Revolution ETF opened new positions in Alamar Biosciences, Biontech, Eli Lilly, and Generate Biomedicines, while exiting Amgen, Standard Biotools, Incyte, Veeva Systems, Vertex Pharmaceuticals, and Caris Life Sciences. The fund added to Tempus Ai and Intellia Therapeutics, and substantially increased Compass Pathways and Genedx Holdings. It trimmed Twist Bioscience, Guardant Health, Butterfly Network, and Ionis Pharmaceuticals, among others.
Full April 2026 recap →